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Abstract
Background:  In South Africa, where health care resources are limited, it is important to ensure
t h a t  d r u g s  p r o v i s i o n  a n d  u s e  i s  r a t i o n a l .  T h e  E s s e n t i a l  D r u g  L i s t  i n c l u d e s  d e p o t
medroxyprogesterone acetate (DMPA) and norethisterone oenanthate (NET-EN) as injectable
progestagen-only contraceptives (IPCs), and both products are extensively used.
Objectives and Methods:  Utilisation patterns of the injectable contraceptive products DMPA
and NET-EN are compared in the context of current knowledge of the safety and efficacy of these
agents. Utilisation patterns were analysed by means of a Pareto (ABC) analysis of IPCs issued from
4 South African provincial pharmaceutical depots over 3 financial years. A case study from rural
KwaZulu-Natal, South Africa, is used to examine utilisation patterns and self-reported side effects
experienced by 187 women using IPCs.
Results:  IPCs accounted for a substantial share of total state expenditure on drugs. While more
DMPA than NET-EN was issued, NET-EN distribution from 2 depots increased over the 3-year
period. Since DMPA was cheaper, if all NET-EN clients in the 1999/2000 financial year (annualised)
had used DMPA, the 4 depots could have saved 4.95 million South African Rands on product
acquisition costs alone. The KZN case study showed slightly more NET-EN (54%) than DMPA
(46%) use; no significant differences in self-reported side effects; and that younger women were
more likely to use NET-EN than DMPA (p = 0.0001).
Conclusions:  Providing IPCs on the basis of age is not appropriate or cost effective. Rational use
of these products should include consideration of the cost of prescribing one over another.
Introduction
Affordability of drugs by developing countries is current-
ly a topic of heated debate. In South Africa, where finan-
cial resources for health care are limited, and where
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health care costs are expected to soar as the HIV epidem-
ic escalates, it becomes increasingly important to ensure
that all drugs are rationally provided and used. The in-
jectable progestagen-only contraceptives (IPCs) depot
medroxyprogesterone acetate (DMPA) and norethister-
one oenanthate (NET-EN) are by far the most widely uti-
lised contraceptives in South Africa, especially amongst
younger users and women living in rural areas [1]. Both
drugs are on the South African Essential Drug List [2]
and are available free of charge at public sector primary
health care facilities. Although not extensively docu-
mented, it is claimed that there has been a shift away
from the predominant use of DMPA, which is given every
12 weeks, to NET-EN, given every 8 weeks, especially
amongst younger, nulliparous women [3, 4]. Combined
injectable contraceptives (CICs), which contain a combi-
nation of oestrogen and progestagen, are not registered
for use in South Africa.
The World Health Organisation's general criteria - safe-
ty, affordability, necessity and efficacy - for inclusion on
the Model List of Essential Drugs (EDL) [5] provide a
useful basis upon which to make decisions about drug se-
lection and rational use. Taking into account published
findings on efficacy, reversibility, side effects and safety,
this paper analyses IPC supply patterns and costs from
four pharmaceutical depots, and describes a case study
of IPC utilisation patterns and side effects in a rural sub-
district of KwaZulu-Natal, South Africa. Based on these
analyses, appropriate recommendations for the rational
use of IPCs are made.
What the literature tells us
Published clinical trials and reviews on efficacy, side ef-
fects, reversibility and safety of DMPA and NET-EN were
sought by means of computerized and hand searches.
Copies of relevant publications and citations from these
publications were obtained and reviewed. Relevant in-
ternational and South African policy documents were
also reviewed. This extensive search revealed that:
DMPA is better researched than NET-EN, few studies di-
rectly compare DMPA and NET-EN, few clinical trials
have been undertaken in Southern Africa, few clinical
studies have been undertaken amongst young users, and
most published studies, upon which review after review
are based, were undertaken in the 1970s and early 1980s.
Methodological differences in subject recruitment, ex-
clusion criteria, frequency and nature of procedures for
follow-up, types of observations made, method of re-
cording, methods of analysis and large intersite variabil-
ity in some studies, make it difficult to evaluate the
published data. Trussel et al. provide a useful account of
difficulties in analysing and comparing contraceptive ef-
ficacy trials [6]. Nevertheless, to the extent that this is
possible, a comparative synopsis of the efficacy, side ef-
fects, delay in return to fertility and safety of DMPA and
NET-EN is provided in this section. It is not the purpose
of this paper to provide a detailed review, but merely to
highlight relevant findings. The authors can be contacted
for a more extensive bibliography.
Both IPCs are demonstrably highly effective. There are
minor differences in published efficacy rates of both
drugs depending on the study, timing of the first injec-
tion, the population, body weight, dosage regimen and
provider training. An illustration of the high efficacy of
these two products is provided by a World Health Organ-
isation (WHO) comparative trial [7]. According to this
study the efficacy of DMPA given every 90 days and
NET-EN given every 60 days are comparable, with a cu-
mulative 2-year pregnancy rate of 0.4 per 100 woman-
years. In an evaluation of 5 large controlled multicentre
studies, Kaunitz [8] reported that there were only 24
pregnancies among 7 849 women using DMPA for 122
496 patient-months. Trussel et al. [6] provide "summary
estimates of contraceptive failure" and give the lowest
expected, and typical percentage, of accidental pregnan-
cies in the United States, during the first year of use, as
0.3 for DMPA and 0.4 for NET-EN (unspecified dose in-
terval).
There is little direct comparative data on the reversibility
of DMPA and NET-EN. While return to fertility is report-
ed by some reviewers to be more rapid with NET-EN [9,
10], more recently, Bigrigg et al. [11] in examining early
data, suggest that there is no delay in return to fertility
with DMPA use, if one considers the methodological bias
of early studies, which did not take in to account the date
of the last DMPA injection. They state further that "if
there is a delay it is not statistically significant and is less
than 30 days". Kaunitz gives the shortest reported time
before fertility is returned with DMPA, as 4 months after
the last injection i.e. 4 weeks after the due date of the
next injection [8] and, according to Hatcher et al. return
to fertility is delayed by DMPA for about 4 months longer
on average, compared with the combined oral contracep-
tive method, intrauterine contraceptive device, and con-
doms [12].
The poor side effect profile of progestagen-only injecta-
bles is extensively documented. The most frequently re-
ported side effects, and those most likely to result in
discontinuation, are menstrual disturbances such as
amenorrhoea, irregular bleeding and heavy bleeding [3,
13]. Menstrual irregularities are reported to occur more
often with DMPA than with NET-EN use. For instance,
the WHO clinical trial undertaken in 1983 compared
menstrual disturbances resulting from DMPA given at
90-day intervals, with NET-EN given every 60 days and
with NET-EN given every 60 days for 6 months and thenBMC Health Services Research (2001) 1:4 http://www.biomedcentral.com/1472-6963/1/4
every 84 days [7]. Significantly less amenorrhoea was re-
ported by NET-EN users (on both dosage regimens),
than by DMPA users. Amenorrhoea was also found to re-
sult in significantly higher discontinuation rates with
DMPA users than with NET-EN. During the first six
months of use, both dosage regimens of NET-EN were
reported to result in more defined cyclic patterns and
fewer prolonged bleeding and spotting episodes than
DMPA, but similar discontinuation rates were found
with the two products. However, in a study undertaken
in Egypt, despite the more frequent occurrence of men-
strual irregularities with DMPA, better one-year contin-
uation rates were found with DMPA than with NET-EN
[14]. Weight gain is also a commonly reported side effect
and in comparing DMPA and NET-EN, the findings on
weight gain appear to be similar. A multinational WHO
comparative clinical trial found no statistical difference
in weight gain between NET-EN and DMPA (both ad-
ministered at 12 week intervals) after a year of use - the
weight gain with NET-EN was reported as 1.5 kg and
with DMPA was 2.0 kg [15]. Headache was the most
common non-menstrual side effect reported in this com-
parative trial and was more frequently reported by
DMPA users than NET-EN users, however, it is impor-
tant to note that in this study, NET-EN was administered
every 12 weeks.
IPCs are considered to be relatively safe contraceptive
methods [16, 17] and recent studies indicate that there is
little reason to be concerned about either DMPA or NET-
EN causing an increased risk of breast cancer [18]. How-
ever, the possible effect of DMPA on bone density, partic-
ularly in adolescents and long-term users is cause for
concern [19]. Little is published on the possible effect of
NET-EN on bone density. Findings from prospective
studies in progress are awaited.
The World Health Organization's Medical Eligibility
Criteria for Contraceptive Use classifies DMPA and
NET-EN together, and makes no differentiation between
the two in regard to their side effects or contraindica-
tions [20]. The only restriction this document makes
about age, for IPC use, is that "For women under 16 years
of age, there are theoretical concerns regarding hypo-
oestrogenic effects...." p.54. The WHO states further that
there is no need to restrict use of progestagen-only con-
traceptive methods for nulliparous women. The Primary
Health Care Essential Drugs List for South Africa pro-
vides no guidelines with respect to the circumstances un-
der which DMPA rather than NET-EN should be
prescribed (or vice versa) [2].
Methods
Supply patterns and costs
Consumption figures of IPC stock issued from provincial
pharmaceutical depots were requested from the Deputy
Director, Procurement of the South African National De-
partment of Health. Data for DMPA and NET-EN were
made available for the KwaZulu-Natal (KZN), Guateng
and Free State Provincial Pharmaceutical depots and for
the Port Elizabeth depot, which serves the western part
of the Eastern Cape Province. These four provinces (of
nine South African provinces) represent over 50% of the
total South African population. Gauteng has a mostly ur-
ban population and KZN and Eastern Cape are more ru-
ral. The following data were analysed for financial years
1997/8, 1998/9, and for 1/04/99 to 7/12/99 of the 1999/
2000 financial year:
• Position number on Pareto (ABC) analyses for DMPA
and NET-EN. An ABC analysis is a method which ranks
drugs according to their annual usage (unit cost times
annual consumption). Class A items are the 10 to 20 %
which account for 75 to 80% of the funds spent. Class B
items have an intermediate contribution to total expend-
iture, whereas Class C items (the majority of items) ac-
count for a small percentage of funds spent. ABC
analyses are used to identify priority cost drivers for in-
tervention [21].
• Number of units of each item issued in the same time
period per depot.
• Total cost of each item per time period per depot (at
constant 1999 prices).
• Current and previous tender prices for DMPA and
NET-EN. Note exchange rate: 1 British Pound  11
South African Rands.
Case study: use patterns and side effects
Prevalence of IPC use was determined by means of a
community-based cross-sectional survey undertaken in
a rural sub-district in northern KZN, South Africa. Com-
mencing from a randomly selected starting point, every
second household was chosen until 40% of households in
the sub-district had been visited. In this way, 849 house-
holds of an estimated 2088 were selected and, one wom-
an from each household, in the age range 15 to 49, was
randomly selected for interview. Verbal and written ex-
planations of the study were provided to each woman se-
lected (in Zulu and/or English) and consent to
participate in the study was requested. In all, 848 women
were interviewed and no-one refused to participate. Pri-
or to commencing the survey, workshops and meetings
were held to introduce the study to local traditional lead-
ers, community health workers, and health service pro-BMC Health Services Research (2001) 1:4 http://www.biomedcentral.com/1472-6963/1/4
viders. Ethical clearance for the study was provided by
the Ethics Committee of the University of Durban-West-
ville.
Each woman selected was asked if she was currently us-
ing an IPC and those who were, were asked whether they
were using DMPA or NET-EN. Data were collected by
means of an extensive structured interview, including
questions on demographic characteristics, reasons for
method selection, and problems and side effects experi-
enced. Interviews were conducted in Zulu, between Sep-
tember and December 1998. They were conducted
during the day from Mondays to Fridays, but where a se-
lected woman was not home, a revisit was made in the
evening or on a Saturday. Data were coded, double en-
tered and analysed using Epi-Info Version 6.43 and the
SAS Version 6.12.
Table 1: Acquisition costs of injectable contraceptive products: 1997/8, 1998/9, 1999/2000
Product Cost per vial (SAR*)
1997/8 1998/9 1999/2000
DMPA
Innovator product (Pharmacia Upjohn) 2.17 4.56 4.78
Generic product (Aspen Pharmacare) -- # 2.07 4.29
NET-EN
Innovator product (Schering) 4.10 4.28 4.78
*Exchange rate: 1 British Pound  11 South African Rands (SAR) # Tender not awarded




D M P A 344
N E T - E N 232
KWAZULU-NATAL
D M P A 464
NET-EN 19 19 19
FREE SATE
D M P A 235
N E T - E N 556
PORT ELIZABETH
D M P A 363
N E T - E N 444BMC Health Services Research (2001) 1:4 http://www.biomedcentral.com/1472-6963/1/4
Results
Supply patterns and costs
Cost of injectable contraceptive products
DMPA products issued at primary health care outlets in
the three financial years analysed were obtained from
the original patent holder (Pharmacia-Upjohn) and a ge-
neric manufacturer (Aspen Pharmacare). NET-EN was
available only from the innovator (Schering). Table 1
shows that the acquisition cost of a vial of both DMPA
and NET-EN products increased every year, and that the
cost of both DMPA products rose particularly steeply. In
the 1999/2000 financial year, the generic product, was
almost the same price as the innovator product. Their
costs were exactly the same in the 1999/2000 fiscal year.
Since DMPA is given less frequently than NET-EN, cost
per couple years of protection (CYP) provides a more ac-
curate cost comparison of DMPA and NET-EN. Based on
the 1999/2000 state tender prices for the DMPA and
NET-EN innovator products, the cost per couple year
was SAR28.68 for NET-EN (6 vials per year) and
SAR19.12 for DMPA (4 vials per year). If the calculation
were based on the DMPA generic product price, use of
DMPA would be even cheaper (SAR17.16). It should be
noted that the cost of syringes, needles and swabs, per-
sonnel costs and client transport and time were not in-
cluded in the calculations. These costs can be
considerable and are obviously higher for NET-EN be-
cause it is administered more frequently.
Analysis of annual expenditure on DMPA and NET-EN
In all 4 depots, both IPCs consumed an important share
of total drug expenditure (table 2). A Pareto analysis
shows that both DMPA and NET-EN appeared in the top
10 in each year (based on actual volumes multiplied by
constant 1999 prices), with the exception of NET-EN in
KZN where it was19th in 1997/8, 1998/9 and 1999/2000.
More was spent on NET-EN than DMPA in Gauteng in
all 3 years, but less in the other 3 depots. Only in 1998/9
in the Port Elizabeth area was more spent on NET-EN
than DMPA. Total annualised expenditure on both prod-
ucts in the 4 depots in 1999/2000 was projected to be
SAR28.77 million.
Ratio of NET-EN:DMPA issued
The ratios of NET-EN:DMPA issued from the 4 depots
were calculated based on CYP rather than on number of
vials issued. As shown in Figure 1, DMPA was increasing-
ly used in Port Elizabeth where the ratio of NET-EN:DM-
PA decreased from 0.64 in 1997/8 to 0.57 in 1999/2000.
In Free State the market share was more or less stable
(0.42, 0.44, 0.40). A similar picture emerged in KZN
(0.22, 0.23, 0.25), with some increase in NET-EN use.
However, in Gauteng, while DMPA was still used most,
NET-EN use was clearly increasing (0.67, 0.73, 0.81).
Counting the cost of injectable contraceptive product choice
If all NET-EN clients in the 1999/2000 financial year
(annualised) had been given DMPA instead, the 4 depots
together might have saved SAR4.95 million. Conversely,
if NET-EN had been issued to all DMPA clients, then the
estimated additional cost in the same year for the 4 de-
pots would have been SAR9.35 million. Savings and ad-
ditional costs would be increased if other costs (surgical
supplies, personnel costs, client transport etc.) were in-
cluded. The savings are calculated on the annualised to-
tal CYP for innovator versions of both DMPA and NET-
EN. If the price of the cheaper generic preparation of
DMPA had been used in the calculation, the savings
would have been greater.
To illustrate the potential savings or additional costs fur-
ther, in KZN, a 9.0% saving on the expected 1999/2000
annual IPC drug bill might have been effected if only
DMPA had been supplied. On the other hand, if only
NET-EN had been available, the additional load would
have been 36.5%. In Gauteng, the savings or additional
costs could have been 18.3% and 22.6% respectively.
Case study: use patterns and side effects
Injectable contraceptive prevalence and cost
All respondents (848) were African, Zulu-speaking
women in the age range 15-49 years. Of these, 187
(22.1%) were using an injectable contraceptive method,
either the innovator product of DMPA or NET-EN. For-
ty-six per cent (86) of the IPC users were using DMPA
and 54% (101) were using NET-EN. The mean age of
DMPA users was 29.6 years (median 29, range 18-49)
and that of NET-EN users was 23.2 (median 23; range
17-37). Younger women were thus more likely to use
NET-EN than DMPA (p = 0.0001). The age distribution
of DMPA and NET-EN users is shown in Figure 2. The
mean length of use was 2.2 years (range 0.1 to 11).
Figure 1
Ratio of NET-EN:DMPA issued from the four pharmaceutical
depots in 1997/8, 1998/9, 1999/2000BMC Health Services Research (2001) 1:4 http://www.biomedcentral.com/1472-6963/1/4
The ratio of NET-EN:DMPA users in this rural sub-dis-
trict was 1.2 to 1. Based on 1999/2000 product costs, by
supplying only DMPA, a saving of 21.3% on the annual
drug bill for IPCs could have been achieved by the local
health facility. On the other hand, if only NET-EN had
been supplied, the annual IPC cost would have increased
by 18.1%. These figures are based on product costs alone.
Reasons for product choice
Current users were asked, by means of an open-ended
question, why they preferred the injectable product they
were using, and the following findings are of note:
- Many DMPA users (42.4%) indicated that they pre-
ferred this product because it was "stronger". On the oth-
er hand, NET-EN was favoured by 36.0% of those using
it as it was regarded as "weaker" or "lighter".
- Concern about delayed return to fertility with DMPA
was expressed by 5.0% of NET-EN users and 14.0% indi-
cated that they chose NET-EN because it did not delay
return to fertility.
- The idea that the NET-EN is for younger women or
teenagers and DMPA for older women was expressed by
14.6% of the IPC users. This preference is clearly reflect-
ed in the age distribution of DMPA & NET-EN users de-
picted in Figure 2.
- Recommendation by health worker was given as one of
the most common reasons for product choice (21.1%).
- Relatively few women (6.5%) mentioned that concern
about side effects influenced choice of either product.
Side effects with injectable contraceptives
IPC users were asked to indicate what side effects, if any,
they were experiencing with DMPA or NET-EN by re-
sponding to a list of 22 possible side effects. Consistent
with the international literature, many women reported
menstrual irregularities such as amenorrhoea, spotting,
heavy periods or irregular periods (table 3). Other side
effects commonly reported were vaginal wetness and
weight gain. The side effect profile for DMPA or NET-EN
users was similar with no significant differences found
between users of the two products in terms of their expe-
rience of side effects.
Discussion
In highlighting key issues in financing family planning
services in Sub-Saharan Africa, Janowitz et al. make the
following statement "Given limited resources, the uni-
versal provision of methods based on demand and with-
out regard to cost will restrict the number of individuals
whose need for family planning services can be met" p.
64 [22]. The balancing of needs and resources becomes
even more challenging when attempting to meet repro-
ductive health needs more broadly. For instance, in de-
veloping countries like South Africa many drugs, such as
antiretrovirals for the management of HIV, are not avail-
able through the public sector. Careful analysis of cur-
rent expenditure on drugs is thus required so that
resources are allocated to meet changing therapeutic
needs.
Findings presented in this paper show that IPCs account
for a substantial share of the total state expenditure on
drugs in South Africa. Of the two IPCs available on the
EDL, DMPA is a cheaper option than NET-EN, even if
only considering acquisition costs. Analysis of supply
patterns from the 4 pharmaceutical depots shows that if
all NET-EN clients had been given DMPA, between 9.0%
and 18.3% of the expected annual drug bill for IPCs could
have been saved per depot. Rational use of drugs cannot
however be based on cost alone and clinical criteria, such
as efficacy, safety, and acceptability of side effects, must
also be considered. The context within which contracep-
tion is provided should also be taken into account. An ex-
tensive review of the literature on IPCs shows little
difference between NET-EN and DMPA in terms of effi-
cacy, safety, reversibility and side effect profile. Howev-
er, a systematic comparative review has not been
published and little clinical data on African women are
available. NET-EN appears to have a slightly better side
effect profile and a slightly shorter delay in return to fer-
tility. DMPA is marginally more effective and is more
convenient as users only have to return to the clinic every
12 weeks rather than after 8 weeks, as is the case for
NET-EN users. As noted earlier, no differentiation in re-
gard to side effects or contraindications of the two prod-
ucts is made by the WHO in terms of its medical
eligibility criteria for contraceptive use [20].
Findings from the KZN case study show that slightly
more NET-EN was used than DMPA. No significant dif-
Figure 2
Age distribution of DMPA and NET-EN usersBMC Health Services Research (2001) 1:4 http://www.biomedcentral.com/1472-6963/1/4
ferences were found in self-reported experience of side
effects. What does emerge clearly is that NET-EN is
viewed as the product of choice for young women and
DMPA for older women. This is reflected in reasons giv-
en for product preference by clients, and in the age dis-
tribution of DMPA and NET-EN users. Further, health
workers appear to play an important role in decision-
making about which IPC product is provided. That dif-
ferent products are considered to be more appropriate
for different age groups may be linked to the perception
that DMPA is "stronger" while NET-EN is "weaker", and
may well be related to concerns about delay in return to
fertility after IPC use, particularly with DMPA. This is
consistent with results from a study undertaken in the
Northern Province of South Africa where providers were
found to recommend NET-EN for younger women based
on their perception that DMPA use may result in perma-
nent infertility, whilst NET-EN was considered ".... less
strong and 'usually reversible' " p. 13 [4].
Age as a criterion for prescribing one or other IPC prod-
uct is not supported by the literature, and some policy
documents and publications specifically debunk the no-
tion that IPCs should be restricted according to age. For
instance, Lande recommends that:
"Providers may need to reassure clients and the public
that injectables do not cause infertility but to note that
women should expect a wait of some months after stop-
ping injectables to become pregnant. Service policies
based on a fear of infertility - in particular, age and parity
restrictions - can be dropped p.7 [23].
Table 3: Side effects most frequently reported by DMPA and NET-EN users
Side Effect DMPA (%) NET-EN (%) P Value*
(n = 84) (n = 95)
Menstrual irregularities
Amenorrhoea # 67.5 58.9 0.240
Spotting 9.5 12.6 0.510
Heavy periods 8.3 7.4 0.792
Irregular periods 3.6 10.5 0.074
Longer periods 2.4 4.2 0.497
Dysmenorrhoea 1.2 1.1 0.930
Vaginal wetness 22.6 14.7 0.175
Weight gain 14.3 8.4 0.214
Loss of libido 10.7 8.4 0.601
Dizziness 10.7 6.3 0.289
Headache 10.7 4.2 0.094
Nausea 9.5 3.2 0.077
Vaginal discharge 8.3 3.2 0.132
Vaginal discharge with odour 7.1 3.2 0.223
# Includes thirty breastfeeding women. Although amenorrhoea was reported as a side effect of IPC use, it could have been lactational amenorrhoea 
* Chi-square (1 degree of freedom, significance tested at the 5% level)BMC Health Services Research (2001) 1:4 http://www.biomedcentral.com/1472-6963/1/4
The second draft of the South African Department of
Health's Draft National Framework & Guidelines for
Contraceptive Services explicitly states that:
"Young clients should not be prevented from using either
DMPA or NET-EN because of their age." p.64 [24].
If one were to embrace the WHO promoted Essential
Drugs concept [5] the decision about which IPC to supply
should be made on cost since DMPA and NET-EN have
comparable efficacy and safety profiles. Based on the
cost analysis presented in this paper, DMPA should be
the product selected. However, reducing contraceptive
options flies in the face of progressive reproductive
health policies which promote expansion of contracep-
tive choice. For instance, the WHO "is giving priority to
improving access to high-quality care in family planning
through a variety of strategies" p.2, and lists one of these
strategies as "promoting the widest availability of differ-
ent contraceptive methods so that people may select
what is most appropriate to their needs and circumstanc-
es" p.2 [20]. The Programme of Action adopted at the In-
ternational Conference on Population and Development
held in Cairo in 1994 recommended that family planning
programmes should "Recognize that appropriate meth-
ods for couples and individuals vary according to their
age, parity, family-size preference and other factors, and
ensure that women and men have information and ac-
cess to the widest possible range of safe and effective
family-planning methods in order to enable them to ex-
ercise free and informed choice" p.39/132 [25]. The Pop-
ulation Council's new approach to contraceptive
introduction in developing countries involves an assess-
ment of the context of contraceptive use in that country,
on the basis of which "recommendations for upgrading
contraceptive services - which could include introducing
new methods, improving the utilisation of existing ones,
and/or removing one or more from the method mix". p.1
[26].
The injectable contraceptive method is an important op-
tion in South Africa, since many women choose this
method because its use does not require partner knowl-
edge or consent [27]. The review of the literature shows
that menstrual irregularities are reported to occur more
often with DMPA than with NET-EN use. In cases where
side effects such as amenorrhoea are particularly prob-
lematic with DMPA, NET-EN may be a good alternative.
By providing NET-EN explicitly as a second-line option,
the range of contraceptive products would be restricted,
but not reduced.
Conclusions and Recommendations
Providing IPCs on the basis of age is not appropriate or
cost effective. Training of health workers and counselling
of clients to correct this misconception is clearly re-
quired. Where clients require immediate return to fertil-
ity upon discontinuing contraception, neither IPC
preparation is ideal. Since DMPA is a cheaper option
than NET-EN, health worker training about the rational
use of injectable contraceptives should include consider-
ation of the cost implications of prescribing one product
over another. DMPA should be considered as the first op-
tion, but where DMPA is not well tolerated, NET-EN
should be available as a second option. It is also recom-
mended that a comparative systematic review of DMPA
and NET-EN be undertaken. Based on the outcome of
this review, consideration may be given to conducting a
comparative clinical trial of NET-EN and DMPA when
used by African women.
Consideration should be given to encouraging the regis-
tration of the combined injectable contraceptive in South
Africa, which has a better side effect profile than the IPCs
[28]. This would be an expensive option thus combined
injectable contraceptives should only be provided where
side effects with the IPCs are intolerable. A better contra-
ceptive option, especially for young people, might how-
ever be the male or female condom with back up of
emergency contraceptive pills to provide dual protection
against unwanted pregnancy and HIV and other sexually
transmitted infections.
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DMPA depot medroxyprogesterone acetate
EDL essential drugs list
KZN KwaZulu-Natal
IPCs injectable progestagen-only contraceptives
NET-EN norethisterone oenanthate
SAR South African Rand
WHO World Health Organisation
Acknowledgements
This study was supported by the Wellcome Trust (Grant Number 050522/
Z/97/Z). We thank Mr J van den Berg (Deputy Director: Procurement, Na-
tional Department of Health) and Mr A Odendaal (Systems Manager, Co-
ordinating Committee for Medical Procurement) for providing access to 
the data from the pharmaceutical depots and for the initial Pareto analysis.
Competing Interests
Have you in the past five years received reimbursements, fees, funding, or 
salary from an organisation that may in any way gain or lose financially from 
the publication of this paper?BMC Health Services Research (2001) 1:4 http://www.biomedcentral.com/1472-6963/1/4
A travel grant was awarded to the main author of this paper in March 1997 
by the manufacturer of the generic depot medroxyprogesterone acetate 
product - one of the drugs mentioned in this manuscript.
Do you hold any stocks or shares in an organisation that may in any way 
gain or lose financially from the publication of this paper? No.
Do you have any other financial competing interests? No.
Are there any non-financial competing interests you would like to declare 
in relation to this paper? No.
References
1. Department of Health of South Africa, Medical Research Council and
Macro International : South Africa demographic and health sur-
vey 1998. Preliminary report. Pretoria, South Africa: Department of
Health 1999
2. National Department of Health : South African standard treat-
ment guidelines and essential drugs list for South Africa. Pri-
mary health care. South Africa: National Department of Health 1998
3. Beksinska ME, Rees VH, Nkoyane T, McIntyre JA: Compliance and
use behaviour, an issue in injectable as well as oral contra-
ceptive use? A study of injectable and oral contraceptive use
in Johannesburg. British Journal of Family Planning 1998, 24(1):21-3
4. Wood K, Maepa J, Jewkes R: Adolescent sex and contraceptive
experiences: perspectives of teenagers and clinic nurses in
the  Northern  Province.  Pretoria,  South  Africa:  Medical  Research
Council 1997
5. Kanji N, Hardon A, Harnmeijer JW, Mandani M, Walt G: Drugs pol-
icy in developing countries. London: Zed Books 1992
6. Trussell J, Hatcher RA, Cates W, Stewart FH, Kost K: A guide to
interpreting contraceptive efficacy studies. Obstetrics and Gyne-
cology 1990, 76:558-67
7. WHO Special Programme of Research Development and Research
Training in Human Reproduction, Task Force on Long-Acting Agents
for the Regulation of Fertility : A multinational comparative clin-
ical trial of long-acting injectable contraceptives: Norethis-
terone enanthate given in two dosage regimens and depot-
medroxyprogesterone  acetate.  Final  report.  Contraception
1983, 28:1-21
8. Kaunitz AM: Clinical use of depo-provera (medroxyprogester-
one acetate) for contraception. A current perspective of sci-
entific, clinical and social issues. In Proceedings of an International
Symposium 19-20 November 1992. Edited by Zambrano D. Johannesburg,
South Africa: Upjohn, 1992
9. Fraser IS, Weisberg E: Fertility following discontinuation of dif-
ferent methods of fertility control. Contraception 1982, 26:389-
415
10. Howard G, Blair M, Fotherby K, Elder MG, Bye P: Seven years clin-
ical experience of the injectable contraceptive, norethister-
one oenanthate. The British Journal of Family Planning 1985, 11:9-16
11. Bigrigg A, Evans M, Gbolade B, Newton J, Pollard L, Szarewski A, Tho-
mas C, Walling M: Depo Provera. Position paper on clinical
use, effectiveness and side effects. British Journal of Family Planning
1999, 25:69-76
12. Hatcher RA, Rinehart W, Blackburn R, Geller JS, Shelton JD: The es-
sentials of  contraceptive  technology. Baltimore:  Johns  Hopkins
University of Public Health, Population Information Program, 1997
13. Fraser  IS:  Menstrual  changes  associated  with  progestogen-
only contraception. Acta Obstetricia et Gynecolologica Scandnavicia
1986, 134:21-7
14. Salem HT, Salah M, Aly MY, Thabet AI, Shaaban MM, Fathalla MF: Ac-
ceptability of injectable contraceptives in Assiut, Egypt. Con-
traception 1988, 38:697-710
15. World Health Organisation Expanded Programme of Research De-
velopment and Research Training in Human Reproduction : Multina-
t i o n a l  c o m p a r a t i v e  c l i n i c a l  e v a l u a t i o n  o f  t w o  l o n g - a c t i n g
injectable  contraceptive  steroids:  Norethisterone  oenant-
hate  and  medroxyprogesterone  acetate.  2.  Bleeding  pat-
terns and side effects. Contraception 1978, 17:395-406
16. Fraser IS: A health perspective of hormonal contraceptives.
Acta Obstetricia et Gynecologica Scandinavica 1986, 134:33-43
17. Kaunitz AM: Long-acting injectable contraception with depot
medroxyprogesterone acetate. American Journal of Obstetrics and
Gynecology 1994, 170:1543-49
18. Shapiro S, Rosenberg L, Hoffman M, Truter H, Cooper D, Rao S, Dent
D, Gudgeon A, van Zyl J, Katzenellenbogen J, Baillie R: Risk of breast
cancer in relation to the use of injectable progestogen con-
traceptives and combined estrogen/progestogen contracep-
tives. American Journal of Epidemiology 2000, 151:396-403
19. Watts NB: Spinal bone density in women using depot me-
droxyprogesterone  contraception  Obstetrics  and  Gynecology
1998, 92:569-73
20. World Health Organisation : Improving access to quality care in
family planning. Medical eligibility criteria for contraceptive
use. Geneva: World Health Organisation. 1996
21. Quick JD, Rankin JR, Laing RO, O'Conner RW, Hogerzeil HV, Dukes
MNG, Garnett A (eds): Managing drug supply. The selection,
procurement, distribution and use of pharmaceuticals, 2nd
ed. West Hartford, Connecticut, USA: Kumarian Press, 1997
22. Janowitz B, Measham D, West C: Issues in the financing of family
planning services in Sub-Saharan Africa. USA: Family Health In-
ternational, 1999
23. Lande RE: New era for injectables. Baltimore, Maryland, USA, Popu-
lation Information Program, Center for Communication Programs, The Johns
Hopkins School of Hygiene and Public Health. Population Reports 1995, Se-
ries K, No 5 
24. Department of Health : National Framework & Guidelines for
Contraceptive  Services.  Republic of  South  Africa.  Second
Draft. Pretoria, South Africa: Department of Health, 1999
25. United Nations Population Information Network : Report of the In-
ternational  Conference  on  Population  and  Development,
Cairo, 5-13 September 1994. New York, United Nations Publications,
1994 [http://www.undp.org/popin/icpd/conference/offeng/poa.html] 
26. Population  Council  :  Contraceptive  introduction.  Expanding
contraceptive choice: Findings from Zambia. Population Briefs,
Spring 1996, 2:2 [http://wwwpopcouncil.org/publications/popbriefs/
pb2%282%29%5F4.html] 
27. Kaufman CE: Reproductive control in South Africa. Policy Re-
search Division Working Paper, No 97. New York: Population Council. 1997
28. Kaunitz AM, Garceau RJ, Cromie MA: Comparative safety, effica-
cy, and cycle control of Lunelle™ monthly contraceptive in-
j e c t i o n  ( m e d r o x y p r o g e s t e r o n e  a c e t a t e  a n d  e s t r a d i o l
cypionate  injectable  suspension)  and  Ortho-Novum  7/7/7
oral contraceptive (norethindrone/ethinyl estradiol tripha-
sic). Lunelle Study Group. 1999, 60:179-87
Pre-publication history




Publish with BioMedcentral and every 
scientist can read your work free of charge
"BioMedcentral will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Paul Nurse, Director-General, Imperial Cancer Research Fund
Publish with BMc and your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours - you keep the copyright
editorial@biomedcentral.com
Submit your manuscript here:
http://www.biomedcentral.com/manuscript/
BioMedcentral.com BioMedcentral.com